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Introduction
The US continues to struggle to reverse an opioid overdose crisis. Overdoses involving any opioid increased from eight-thousand in 1999 to approximately nineteen-thousand in 2007 and to almost forty-eightthousand in 2017 (NIDA, 2019) . Overdose data should be interpreted cautiously however as states differ widely in use of medical, or even non-medical, personnel or analytical chemistry procedures to complete death determinations. The number of overdoses where the substance involved was unspecified on the death certificate ranged from 0% in Washington DC to 51% in Pennsylvania (Buchanich et al. 2018) . The Centers for Disease Control and Prevention (CDC) used a three-tier system (excellent, good, or other/less than good) to classify overdose death determinations with twenty-two states falling into the latter designation (Rudd et al. 2016) .
Interestingly, prescription opioid use, a measure with much more homogenous data collection, peaked in 2011 (Piper et al. 2018 ) and has undergone pronounced reductions for most agents, with the exception of buprenorphine (Collins et al. 2019) . Buprenorphine availability is associated with decreased opioid overdoses (Schwartz et al. 2013) . States that expanded Medicaid saw a seventy percent increase in buprenorphine prescriptions (Wen et al. 2017) .
Several lines of evidence, albeit mostly from non-randomized and non-blind research designs, are suggestive of the potential for medical cannabis (MC) to attenuate opioid use or misuse. The potency of morphine on the rodent tail flick response to an aversive thermal stimuli was greatly enhanced by tetrahydrocannabinol (THC, Smith et al. 1998 ). Human trials have supported the ability of THC to augment the pain reducing effects of morphine and oxycodone (Abrams et al. 2011; Cooper et al. 2018) . Three-quarters of dispensary members reported a reduction in their use of opioids after starting MC (Piper et al. 2017) . The 2017 National Academy of Sciences report stated that evidence was conclusive that cannabis reduces chronic pain in adults, but the magnitude of effect was modest (National Academy of Sciences, 2017). Similarly, examination of a prescription drug monitoring program records revealed that patients were seventeen-fold more likely to stop use of all controlled substances after starting MC (Stith et al. 2018) . States that legalized MC had lower expenditures for prescription medications in Medicare (Bradford & Bradford, 2016) and Medicaid (Bradford & Bradford, 2017 , although see Ozluk, 2017 . One of the most impactful studies was on opioid analgesic and heroin overdoses from 1999 -2010 which made two discoveries. First, states that 4 4 legalized MC had more opioid overdoses relative to those that did not. Second, opioid overdoses declined following MC implementation relative to those states without MC (Bachhuber et al. 2014) . Further examination identified pre-existing state differences in opioid dependence hospitalizations and reductions associated with MC implementation (Shi, 2017) . Findings like these (Lucas, 2017) may have been influential in for eight states (Colorado, Illinois, Missouri, Nevada, New Jersey, New Mexico, New York, and Pennsylvania) including opioid misuse as a qualifying condition for medical cannabis (NORML, 2019) .
The objective of this report was to provide an update to Bachhuber et al. 2014 and examine opioid overdose mortality with the inclusion of additional states that have approved MC. database (https://wonder.cdc.gov/ ). The data was based on death certificates for US residents. Opioid overdose deaths were defined using the International Statistical Classification of Diseases, 10 th revision codes: X40-44, X60-64, X85, Y10-Y14 (Bachhuber et al. 2014) . Only data that was coded for opioids (T40.0-T40.4) was used (Powell & Pacula, 2018) . This included opium, heroin, other opioids, methadone, and other synthetic opioids.
An interrupted time series examined any trends around the time of states' medical marijuana program implementation. Opioid deaths per 100,000 population were obtained. We defined the start dates of medical marijuana programs as the year the state began medical marijuana sales. This data was found on either state's medical marijuana program website, or from local newspaper articles detailing the start of medical marijuana sales.
Only Arizona (implemented in 2012), Connecticut (2014) Two potential confounds were also examined. A two (MC-vs MC+) by two (Medicaid expansion by 2014 or 12/2017) chi-square and a t-test on the CDC's three-tiered classification system (Rudd et al. 2016) for the quality of death certificate reporting (2 = very good/excellent, 1 = good, 0 = less than good based on completeness and 6 6 consistency over time, described further in the Supplemental Figure 1 caption) were completed. Variability was expressed as the SEM. A p value less than 0.05 was considered statistically significant. Heat maps were created using Excel. 7 7 Results Figure 1A shows that overdoses had pronounced elevations over time and were generally higher among MC+ states. Significant differences in opioid overdoses per 100,000 population were identified in '02, '06, and '13 to '17 between MC+ and MC-state. Figure 1B illustrates that the linear-regression slope of opioid overdose over time increased significantly in states without medical marijuana (Pre = 0.10 + 0.08, Post = 0.61 + 0.16, t(16) = 2.88, p < .05). The change in states with medical marijuana did not fulfill conventional statistical thresholds (Pre = 1.26 + 0.40, Post = 2.77 + 0.91, t(11) = 2.01, p = .069). The post-legalization slope was significantly higher in MC+ than MC-( t(11.95) = 2.70, p < .05) states.
Two MC-(11.1%) as compared to eleven MC+ (91.7%) states expanded Medicaid by 2014 (χ 2 (1) = 19.03, p < .0005). The same general pattern was noted when the expansion date was set at 2017 (MC-= 22.2%, MC+ = 91.7%, χ 2 (1) = 13.89, p < .0005). The quality of overdose determinations was twice as large in MC+ states ( t(28) = 2.18, p < .05, Figure 1C ). 8 8
Discussion
This report re-examined and extended upon the seminal report of Bachhuber et al. 2014 . The findings may be considered a partial replication. Their result that states with MC from 1999-2010 had elevated opioid mortality, relative to those without MC, was confirmed with the inclusion of seven additional years ( Figure 1A) . Their finding of opioid overdoses decreasing in the years subsequent to adopting MC as compared to states that did not, was not replicated. In fact, states that previously adopted MC had a significantly greater overdose slopes than those that did not ( Figure 1B) . The preclinical (Smith et al. 1998 ) and epidemiological evidence base (Bradford & Bradford, 2017 National Academy of Sciences, 2017; Stith et al. 2018) indicates that it is plausible that MC could decrease opioid use with its synergistic anti-nociceptive properties (Abrams et al. 2011; Cooper et al. 2018 ) and therefore limit misuse and overdose potential. However, investigations like Bachhuber et al. 2014 assume that overdose determinations are consistently made by medical examiners and coroners across the US (Supplemental Figure 1) . At the very least, any differences should be random and not systematically different based on MC laws. An additional key finding was that this assumption was not warranted ( Figure 1C ) in that states without MC had lower overdose death determination reporting quality using the CDC criteria (Rudd et al. 2016) .
The continued pronounced elevations in opioid overdoses, typically involving poly-substances (Simpson et al. 2019 ) is concerning. These findings, although largely contradictory to Bachhuber et al. 2014) , should not be used to discount that the risk to benefit ratio may still favor MC as another tool that may be endorsed by some chronic pain patients, especially relative to the overdose potential of prescription opioids. As others have recently noted (Shover et al. 2019) , the ecological research design where the unit of analysis is the state might not be best-suited to address this question. State-level MC systems, either established through voter initiative or through their state legislation, may differ on a wide-variety of socio-political characteristics. For example, Medicaid expansion was much more common among MC+ states. The additional resources provided by Medicaid could have provided for additional buprenorphine (Wen et al. 2017 ) which initially decreased opioid overdoses (Schwartz et al. 2013) . Later, the potency of fentanyl and many fentanyl analogues (Simpson et al. 2019 ) could overcome any cannabis substitution effect (Piper et al. 2017) . The increase in China white variety of heroin which is more common in the eastern US (Mars et al. 2016) and is more susceptible to contamination with white fentanyl than black tar heroin 9 9 likely also contributes to regional differences in the recent overdose surge. This may be crucial because the majority (83.3%) of the MC+ states were east of the Mississippi. Some caveats and future areas of study should be noted. This report was based on US overdoses as reported by the CDC. Five states had more than one-third of their death certificates where the substance involved was unspecified (Buchanich et al. 2018) . The non-uniformity of autopsy procedures (e.g. When did each state, county, or city start testing for fentanyl? Were screens or the more expensive confirmatory testing employed? How many of the two-hundred fentanyl analogues were tested in each municipality and when?) is a substantial challenge to research, and barrier for empirically informed public policy which utilizes this information. Although this would limit the power to detect differences, future research might consider focusing only on the subset of areas where the death determination procedures have been consistently high (e.g. Simpson et al. 2019 ). This study investigated MC and may not generalize to recreational marijuana laws. versus MC-). Opioid overdose slopes three-years before (Pre) and three-years after (Post) state MC implementation (B, a p < .05 versus MC-; b p = .07 versus MC+ Pre, c p < .05 versus MC-Post). Death certification reporting quality (C, Excellent: 2, Good: 1, Less than good: 0; *p < .05).
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Supplemental Figure 1 . Heat map of the US by overdose death certificate reporting quality. Excellent was defined as ≥ 90% of drug overdose death certificates mention at least one specific drug in 2014, with the change in percentage of drug overdose deaths mentioning at least one specific drug differing by <10 percentage points from 2014 to 2015. Good was defined as 80% to <90% of drug overdose death certificates mentioning > one specific drug in 2014, with the change in the percentage of drug overdose deaths mentioning > one specific drug differing by <10 percentage points from 2014 to 2015. The remaining states were classified as less than good. Additional information may be found in Rudd et al. Morbidity & Mortality Weekly Report 2016; 65:1445-52. 
